Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 4, 1994 - Issue 12
Submit an article Journal homepage
4
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Biologicals and Immunologicals Overview: Recent developments in macrolide immunosuppressants

Susan E Wilson Department of Academic Virology, London Hospital Medical College, London, El 2AD
&
Roger Aston Department of Academic Virology, London Hospital Medical College, London, El 2AD
Pages 1445-1460 | Published online: 03 Mar 2008

References to Primarv Literaturess

  • VERZINA C, KUDELSKI A, SEHGAL SN: Rapamycin (AY-22,989), new fungal antibiotic. 1. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot (Tokyo)(1975) 28:721-726. Discovery of rapamycin as an antifungal compound.
  • KINO T, HATANAKA H, HASHIMOTO M, NISHIYAMA M, GOTO T, OKUHARA M, KOHSAKA M, AOKI H, IMANAKA H: FK-506, a novel immunosuppressant isolated from a streptomyces. L Fermentation, isolation, and physio-chemical and biological characteristics. J. Antibiot (To-kyo) (1987) 40: 1249–1255. Discovery of FK506 as a novel immunosuppressant.
  • SINGH K, SUN S, VEZINA C: Rapamycin (AY-22,989), a new antifungal antibiotic. IV. Mechanism of action. J. Antibiot. (1979) 32: 630–645.
  • TOCCI MJ, MATKOVICH DA, COLLIER KA, KWOK P, DU-MONT F, UN S, DEGUDICIBUS S, SIEKIERKA JJ, CHIN J, HUTCHINSON NI: The immunosuppressant FK506 selec-tively inhibits expression of early T-cell activation genes. J. Immunol. (1989) 143: 718–726.
  • DUMONT F.J, STARUCH MJ, KOPRAK S.L, MELINO M.R, SIGAL NH: Distinct mechanisms of suppression of mur-Inc T-cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. (1990) 144: 251–258.
  • DUMONT FJ, MELINO MR, STARUCH MJ, KOPRAK S.L, FISCHER PA, SIGAL N.H: The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T-cells. j Immunol. (1990) 144: 1418–1424.
  • OCHIAI T, NAKAJIMA K, NAGATA M, HORI S, ASANO T,ISONO K: Studies of the induction and maintenance of long term graft acceptance by treatment with FK506 in heterotropic cardiac allo-transplantation. Transplant. (1987) 44: 734.
  • FUNG J, ABU-ELMAGD K, JAIN A, ST1EBER A, CASAVILLAA, STARZ T: A randomised trial of primary liver trans-plantation under immunosuppression with FK506 vs cyclosporine. Transplant. Proc. (1991) 23: 2977.
  • SHAW BW, MARIUN R, STRATTA R, LANGNAS A, DONO-VAN J, SORRELL M: FK506 for rescue treatment of acute and chronic rejection in liver allograft recipients. Trans-plant. Proc. (1991) 23: 2944.
  • SCHREIBER SL: Chemistry and biology of the imtnuno-philins and their immunosuppressive ligands. Science.(1991) 251: 283–287. A comprehensive review comparing the differences in mechanisms of action of CsA, FK506 and rapamycin.
  • LIU J: FK506 and cyclosporhe molecular probes for studying intracellnlar signal transduction. Trends Phar-macol. Sci. (1993) 14: 182–188. Detailed review of interaction of CsA and FK506 in intracellular signalling.
  • NAVIA MA, PEATTIE DA: Structure-based drug design: applications in inununopharmacology and irnmuno-suppression. Trends Pharmacol. Set. (1993) 14: 189–195.
  • HANDSCHUMACHER RE, HARDING MW, RICE J, DRUGGE RJ, SPEICHER DW: Cyclophilin: a specific cytosoloic binding protein for cyclosporin A. Science. (1984) 226: 544–546.
  • TAKAHASHI N, HAYANO T, SUZUKI M: Peptidyl-prolylcis-trans isomerase is the cyclosporin A-binding pro-tein cyclophilin. Nature. (1989) 337: 473–475. One of two groups to report almost simustaneously that PPlase was identical to cyclophilin.
  • FISCHER G, WIT'TMANN LB, LANG K, KIEFHABER T, SCHMID FX: Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature (1989) 337: 476–478.
  • FISCHER G, SCHMID ER: The mechanism of protein folding. Implications of in vitro refolding models for de novo protein folding and translocation in the cell. Biochem. (1990) 29: 2205–2212.
  • SIEKIERKA JJ, HUNG SHY, POE M, UN CS, SIGAL NH: A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activitiy but is distinct from cyclophilin. Nature (1989) 341: 755–757. One of two concurrent reports documenting a major isoforrn of the family of FK506-binding proteins.
  • HARDING MW, GALAT A, UEHLING DE, SCHREIBER SL: A receptor for the immunosuppressant FK506 is a cis-transpeptidyl-prolyl isomerase. Nature (1989) 341: 758–760.
  • STANDAERT RF, GALAT A, VERDINE GL, SCHREIBER SL:Molecular dotting and the overexpression of the hu-man FK506-binding protein FKI3P. Nature (1990) 346: 671–674.
  • MAKI N, SELIGUCHI F, NISHIMAKI J, MIWA K, HAYANO T,TAKAHASHI N, SUZUKI M: Complementary DNA encod-ing the human T-cell FK506-binding protein, a peptklyl prolyl cis-trans isomerase distinct from cyclophilin. Proc. Natl. Acad. Sci. USA (1990) 87: 5440–5443.
  • ICE H: Similarities and differences between human cy-clophilin A and other beta-barrel structures. Structural refinement at 1.63A resolution. J. Mot. Biol. (1992) 228: 539–550.
  • VAN DUYNE GD, STANDAERT RF, KARPLUS PA, SCHREIBER SL, CLARDY J: Atomic structures of the hu-man immunophilin FICBP-12 complexes with FK506 and rapamycin. J. Mol. Biol. (1993) 229: 105–124.
  • PFLUGL G, }CALLEN J, SCHIRMER T, JANSONIUS JN, ZURINIMG, WALKINSHAW MD: X-ray structure of a decameric cyclophilin-cyclosporin crystal complex. Nature (1993) 361: 91–94.
  • FRETZ H, ALBERS MW, GALAT A, STANDAERT RF, LANEWS, BURAKOFF SJ, BIERER BE, SCHREIBER SL: Rapamycin and FK506 binding proteins (immunophilins) J. Am. Chem. Soc (1991) 113: 1409–1411.
  • JIN Y-J, ALDERS M.W, LANE W.S, BIERER BE, SCHREIBERS.L, BURAKOFF SJ: Molecular cloning of a membrane-as- sociated human FK506- and rapamycin-binding pro-tein, FICBP-13. Proc. Natl. Acad. Sci. USA. (1991) 88: 6677–6681.
  • GALAT A, LANE WS, STANDAERT RF, SCHREIBER SL: Arapamycin-selective 25-kDa immunophilin. Biochem. (1992) 31: 2427–2434.
  • HUNG DT, SCHREIBER SL: cDNA cloning of a human25kDa FK506 and Rapamycin binding protein. Biochem. Biophys. Res. Comm (1992) 184: 733–738.
  • YEM AW, TOMASSELLI AG, HEINRIKSON RI, ZURCHER-NEELY H, RUFF V A, JOHNSON RA, DEIBEL MR: The lisp 56 component of steroid receptor complexes binds to Immobilised FK506 and shows homology to FICIIP-12 and FKBP-13. J. Biol. Chem. (1992) 267: 2868–2871.
  • BIERER BE, MATTILA PS, STANDAERT RF, HERZENBERGLA, BURAKOFF SJ, CRABTREE G, SCHREIBER SL: Two distinct signal transmission pathways in T-lympho-cytes are inhibited by complexes formed between an immunophRin and either FK-506 or rapamycin. Proc. Natl. Acad. Set. USA. (1990) 87: 9231–9235. First report that the two structurally related macrolides rapamycin and FK506 mediate their inhibitory actions at distinctly different phases of the cell cycle.
  • VAN DUYNE GD, STANDAERT RF, KARPLUS pA, SCHREIBER SL, CLARDY J: Atomic structure of FICI3P-FK506, an immunophilin-immunosuppressant com-plex. Science (1991) 252: 839–842.
  • WANG T, DONAHOE PK, ZERVOS AS: Specific interaction• of type I receptors of the TGF-I3 family with the immu-nophilin FICBP-12. Science (1994) 265: 674–676. First report that type I TGF-P may represent natural ligand for FKBP–12
  • KOLTTN Y, FAUCETTE L, BERGSMA DJ, LEVY MA, CAP-FERKEY R, KOSER PL, JOHNSON RK, LN1 GP: Rapamycin-sensitivity in Saccbaromyces cerevisiae is mediated by a peptidyl-prolylcis-trans isomerase related to human FK506-binding protein. Mot CellBiol.(1991) 11: 1718–1723.
  • MCKEON F: When worlds collide: immunosuppressants meet protein phosphates. Cell (1991) 66:823–826.
  • WALSH CT, ZYDOWSKY LD, MCKEON FD: Cyclosporin A, the cyclophilin class of peptidyl prolyl isomerase, and blockade of T-cell signal transduction. J. Biol. Chem. (1992) 267: 13115–13118.
  • SIGAL NH, DUMONT FJ: Cydosporin A, FK506, and rapamycin: pharmacologic probes of lymphocyte sig- nal transduction. Annu. Rev. Immunol. (1992) 10: 519–560. Excellent review of molecular mechanisms of action of CsA, FK506 and rapamycin.
  • DURETTE PL, BOGER J, DUMONT F, FIRESTONE R, FRANK-SHUN RA, KOPRAK SL, UN CS, MELINO MR, PESSOLANO AA, PISANO J, SCHMIDT JA, SIGAL NH, STARUCH MJ, WITZEL BE: A study of the correlation between cyclo-philin binding and in vitro immunosuppressive activity of cyckmporin A and analogues. Transplant. Proc. (1988) 20: 51–57. SIGAL NH, DUMONT F, DURETTE P, SIEICIERKA JJ, PETER-SON L, RICH DH, DUNLAP BE, STARUCH MJ, MELINO MR, KOPRAK SL, WILLIAMS D, WITZEL B, PISANO JM: Is cyclo-philin involved in the imnumosuppressive and neph-rotoxic mechanism of action of cyclosporin A? J. Exp. Med. (1991) 173: 619–628. OOComprehensive report dissecting the potential molecular basis of the SAR-related immunosuppressive versus the nephrotoxic properties of CsA.
  • BIERER BE, SOMERS PK, WANDLESS TJ, BURAKOFF SJ, SCHREIBER SL: Probing immunosuppressant action with a nonnatural immunophilin ligand. Science (1990) 250: 556–559.
  • FRIEDMAN J, WEISSMAN I: Two cytoplasmic candidatesfor immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA. Cell (1991) 66: 799–806.
  • LIU J, FARMER J. D, LANE W.S, FRIEDMAN J, WEISSMAN I, SCHREIBER S.L: Calcineurin is a common target of cyclo-philin-cyclpsporin A and FKBP-FK-506 complexes. Cell (1991) 66:807–815.
  • LIU J, ALBERS MW, WANDLESS TJ, LUAN S, ALBERG DG, BELSIIAW PJ, COHEN P, MACINTOSH C, KLEE CB, SCHREIBER SL: Inhibition of T-cell signaling by immu-nophilin-ligand complexes correlates with loss of cal-cineurin phosphatase activity. Biochem. (1992) 31: 3896–3899.
  • KLEE CB, DRAE IIA GF, HUBBARD MJ: Advances in enzy-mology and related areas of molecular biology. Meister A, (Ed.)61: 149–209, John Wiley & Sons.
  • LIN CS, BOLTZ RC, SIEKIERKA JJ, SIGAL NH: FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell Immunol. (1991) 133: 269–284.
  • JAIN J, MCCAFFREY PG, VALGE-ARCHER VE, RAO A: Nucicear factors for activated T-cells containingFos and Jun. Nature. (1992) 356: 801–804.
  • FLANAGAN WM, CORTHESY B, BRAM RJ, CRABTREE GR: Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin. Nature. (1991) 352: 803–807.
  • HEITMAN J, MOVVA NR, HALL MN: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. (1991) 253: 903–909.
  • MORRIS RE. Rapamycin: FK506s fraternal twin or distant cousin? Immunol. Today. (1991) 5: 137–140.
  • METCALFE S, MILNER J: Evidence that FK506 and rapamy-cin block T-cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PPI and PF2A. Transplant. (1991) 51: 1318–1320.
  • STURGILLWU J: Recent progress in characterizationof protein kinase cascades for phosphorylation of ribo-somal protein S6. Biochim. Biophys. Acta. (1991) 1092: 350–357.
  • THOMAS G: Map kinase by another name smells just as sweet. Cell (1992) 68: 3–6.
  • LANE HA, FERNANDEZ A, LAMB NJC, THOMAS G: p7056is function is essential for GI progression. Nature (1993) 363: 170–172.
  • CHUNG J, KUO J. C, CRABTREE G. R, BLENIS J: Raparny-cin-FKBP specifically blocks growth-dependent activa-tion of and signaling by the 70kd S6 protein kinase. Cell (1992) 69: 1227–1236.
  • PRICE DJ, GROVE JR, CALVO V, AVRUCH J, BIERER BE: Rapamycin-induced inhibition of the 70-kilodahon S6 protein kinase. Science (1992) 257: 973–977.
  • TERADA N, LUCAS JJ, SZEPESI A, FRANKLIN RA, TAKASE K, GELFLAND EW: Rapamycin inhibits the phosphory-lation of p70s6K in IL-2 and mitogen-activated human T-cells. Bichem. Biophys. Res. Acta. (1992) 186: 1315–1321.
  • ERIKSON RE: Structure, expression, and regulation of protein kinases involved in the phosphorylation ofribosomal 56.1 Biol. Chem. (1992) 266: 6007–6010. Good review of role of protein kinases involved in phosphorylation of ribosomal 56.
  • KUO CJ, CHUNG J, FIORENTINO DF, FLANAGAN WM, BLENIS J, CRABTREE GR: Rapamycin selectiviely inhibits interleukin-2 activation of p70s6K. Nature. (1992) 358: 70–73.
  • TERADA N, LUCAS II, SZEPESI A, FRANKLIN RA, DOMENICO J, GELFLAND EW: Rapamycin blocks cell cycle progression of activated T-cells prior to events characterisitic of the middle to late GI phase of the cycle. J. Cell Physiol. (1993) 154: 7–15.
  • DE GROOT RP, BALLOU LM, SAAONE-CORSI P: Positive regulation of the cAMP-responsive activator CREM by the p70s6K: An alternative route to mitogen-induced expression. Cell (1994) 79: 81–91.
  • MASSAGUE J, ATTISANO L, WRANA JL: Trends. Cell Biol. (1994) 4: 172–178.
  • WRANA JL, ATTISANO L, WIESER R, VENTURA F, MAS-SAGUE J: Mechanism of activation of the TGF-p receptor. Nature (1994) 370: 341–347. Detailed account of molecular mechanisms involved in TGF-13 receptor signalling pathways.
  • ATTISANO L, WRANA JL, LOPEZ-CASILLAS F, MASSAGUE TGF-f3 receptors and actions. J. Biochim. Biophys. Acta. (1994) 1222: 71–80.
  • ANDRIEU J-M, EVEN P, VENET A: AIDS and related syn-dromes as a viral-induced autohrunune disease of the Immune system: an anti-MHC II disorder. Therapeutic Implications. AIDS. Res. (1986) 2: 163–174. Excellent detailed review of early- and late-stage clinical and immu-nological manifestations of HIV infection and comparison with documented autoimmune mechanisms.
  • GRANT M. D., WEAVER M. S., TSOUKAS C, HOFFMAN G.W: Distribution of antibodies against denatured colla-gen in AIDS risk groups and homosexual AIDS patients suggests a link between autoimmunity and the immu-nopathogenesis of AIDS. J. Immunol. (1990) 144: 1241–1250.
  • MORROW WJW, ISENBERG DA, SOBOL RE, STRICICER RB,KIEBER-EMMONS T: AIDS virus infection and autoirrunu-nity. A perspective of the clinical, immunological and molecular origins of the autoallergic pathologies asso-ciated with HIV disease. Clin. Immunol. Immunopathol. (1991) 58: 163–180. Comprehensive review of clinical and immunological autoimmune component of HIV-1 infection and disease.
  • ZIEGLER J. L, STITES D. P: Hypothesis: AIDS is an autoim-• mime disease directed at the immune system and trig-gered by a lymphotropic retrovirus. Clin. Immunol. Immunopathol. (1986) 41: 305–313. First comprehensive review of parallels between HIV-1 disease and autoimmune disease.
  • HABESHAW JA., HOUNSELL E, DALGLEISH AG: Does theHIV envelope induce a chronic graft-versus-host-like • disease? Immunol. Today (1992) 13 (6): 207–210. Hypothesis outlining putative role of HIV-1 envelope gp120 mimicry and induction of deregulation of immunological mechanisms which parallel chronic GVHD.
  • ANDRIEU J-M, EVEN P, VENET A, TOURANI J-M, STERN M, LOWENSTEIN W, AUDROIN C, EME D, MASSON D, SORS H, ISRAELBIET D, BELDJORD J: Effects of cyclosporin on T-cell subsets in human inuriunodeficiency virus dis-ease. Clin. Immunol. Immunopathol. (1988) 46: 181–198. References to Patent Literature

References to Primarv Literaturess

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.